PDCD1 and cancer: In addition, previous studies have demonstrated that apatinib (a well-known TKI) combined with an anti-PD-1 antibody could increase CD8+ TIL cells and restore function in exhausted CD8+ T-cells in anti-PD-1 antibody-resistant cancers [21].